



The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

04 October 2005

Dear Sir,

Resonance Health awarded WA State Government Health Supply Contract

Key Points:

- **WA Patients to access FerriScan® at no direct cost**
- **WA State Government to reimburse Resonance Health with commercial fee**
- **FerriScan to replace liver biopsy for Liver Iron Concentration (LIC) measurements**
- **Potential for other States to follow contract model**

4th October 2005: Resonance Health Ltd (ASX: RHT) today announced that its wholly-owned subsidiary Resonance Health Analysis Services (RHAS), has been awarded a Department of Health, Government of Western Australia (WA) Health supply contract.


The contract ensures the supply of the FerriScan® technology to all capable public hospital Magnetic Resonance Imaging (MRI) centres in the State. The first MRI centre to offer FerriScan as part of the contract is located at Fremantle Hospital.

Patients will now be able to access FerriScan through the WA public hospital system with no direct cost to the patient. Costs associated with the provision of the FerriScan service are reimbursed in full under the contract, with RHAS receiving its standard commercial fee for the provision of the FerriScan service.

“We anticipate that this supply contract in WA will provide a foundation to expand the provision of a reimbursed FerriScan service into other States, allowing greater access to FerriScan and improved health outcomes for people at risk from the debilitating effects of iron overload,” said Dr James Williams, Managing Director of Resonance Health.

RHAS was awarded the supply contract after an exemption from tender was granted on the basis that RHAS was the sole supplier of a regulatory cleared MRI method for non-invasive measurement of Liver Iron Concentration (LIC).

Approximately 1 in every 200 Australians have the genetic defect, which causes the iron overload condition “Hereditary Haemochromatosis”. It is estimated that 1000 West Australians are currently under clinical management for their iron overload conditions with thousands more at risk and requiring evaluation.



Further information:

About 'Iron Overload' Conditions

Having too much iron in the body and being unable to get rid of this excess is one of the world's most common hereditary disorders. The disorders, often collectively termed as 'Iron Overload', are generally classified as primary (e.g. hereditary haemochromatosis – HHC) or secondary (e.g. acquired – transfusional iron overload such as thalassemia). Approximately 11 million people globally, who have 'clinically significant' iron loading would benefit from improved diagnosis and management of their condition.

Haemochromatosis is a genetic disorder that causes iron deposition in the liver and other organs of the body, resulting in iron overload. The condition frequently remains undiagnosed because of lack of awareness, its long latency period, and its non-specific symptoms. Thalassemia, a genetic blood disorder and a very severe and debilitating form of anaemia, also results in iron overload due to the requirement for frequent blood transfusions.

About Resonance Health Ltd


Resonance Health (ASX: RHT) is an Australian Healthcare company specialising in the development and commercialisation of magnetic resonance imaging (MRI)-related technology for the quantitative measurement of iron levels in the human body.

Our mission is to develop and market our technologies to assist in the diagnosis and management of patients suffering from iron-related conditions, whilst delivering significant added value for our MRI customers who deliver our service through their networks.

In 2005, RHAS began the global commercial launch of FerriScan, its world leading non-invasive tool for measuring liver iron levels. The FerriScan service involves an MRI scan followed by off-site processing of the images by RHAS using its patented methodology to generate the liver iron concentration result. MR data is transmitted electronically via a secure data process to the RHAS analysis centre from anywhere in the world. The test requires no new equipment purchase at the MRI centre level.

FerriScan provides a significant improvement over current blood markers and invasive surgical procedures. This improvement leads to increased clinical efficiency and accuracy in diagnosis, in addition to allowing optimisation of treatment programs for iron-related disorders. FerriScan is now positioned to become a routine part of the clinical diagnosis and management of iron loading disorders as well as playing a major role in the testing and monitoring of drugs used to treat these conditions.

FerriScan has received regulatory clearance to be marketed in Australia, USA, UK and Europe. Further information about Resonance Health and FerriScan® can be obtained from the following websites: www.resonancehealth.com and www.ferriscan.com.



Media and Investor Relations	Resonance Health
Rebecca Piercy Buchan Consulting T - +61 3 9866 4722 M – 0422 916 422 Email: rpiercy@bcg.com.au	Dr James Williams Managing Director Resonance Health Limited T - +61 8 9286 5300 M - 0409 050 519 Email: jamesw@ferriscan.com